全文获取类型
收费全文 | 230831篇 |
免费 | 18517篇 |
国内免费 | 7259篇 |
专业分类
耳鼻咽喉 | 1306篇 |
儿科学 | 7959篇 |
妇产科学 | 1820篇 |
基础医学 | 21186篇 |
口腔科学 | 3804篇 |
临床医学 | 24081篇 |
内科学 | 57928篇 |
皮肤病学 | 2861篇 |
神经病学 | 27125篇 |
特种医学 | 6534篇 |
外国民族医学 | 4篇 |
外科学 | 17448篇 |
综合类 | 30994篇 |
现状与发展 | 34篇 |
一般理论 | 9篇 |
预防医学 | 20743篇 |
眼科学 | 2591篇 |
药学 | 15981篇 |
199篇 | |
中国医学 | 10143篇 |
肿瘤学 | 3857篇 |
出版年
2024年 | 672篇 |
2023年 | 4814篇 |
2022年 | 8777篇 |
2021年 | 12400篇 |
2020年 | 11584篇 |
2019年 | 8752篇 |
2018年 | 8643篇 |
2017年 | 8535篇 |
2016年 | 8876篇 |
2015年 | 8633篇 |
2014年 | 16159篇 |
2013年 | 17747篇 |
2012年 | 13284篇 |
2011年 | 14334篇 |
2010年 | 11336篇 |
2009年 | 10955篇 |
2008年 | 10901篇 |
2007年 | 10557篇 |
2006年 | 9370篇 |
2005年 | 7783篇 |
2004年 | 6658篇 |
2003年 | 5747篇 |
2002年 | 4843篇 |
2001年 | 4161篇 |
2000年 | 3439篇 |
1999年 | 2966篇 |
1998年 | 2852篇 |
1997年 | 2536篇 |
1996年 | 2261篇 |
1995年 | 2049篇 |
1994年 | 1863篇 |
1993年 | 1631篇 |
1992年 | 1543篇 |
1991年 | 1366篇 |
1990年 | 1099篇 |
1989年 | 926篇 |
1988年 | 869篇 |
1987年 | 780篇 |
1986年 | 695篇 |
1985年 | 804篇 |
1984年 | 680篇 |
1983年 | 417篇 |
1982年 | 502篇 |
1981年 | 415篇 |
1980年 | 318篇 |
1979年 | 270篇 |
1978年 | 213篇 |
1977年 | 189篇 |
1976年 | 155篇 |
1975年 | 54篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
《Journal of pediatric surgery》2023,58(6):1213-1218
IntroductionEndoscopic surveillance guidelines for patients with repaired esophageal atresia (EA) rely primarily on expert opinion. Prior to embarking on a prospective EA surveillance registry, we sought to understand EA surveillance practices within the Eastern Pediatric Surgery Network (EPSN).MethodsAn anonymous, 23-question Qualtrics survey was emailed to 181 physicians (surgeons and gastroenterologists) at 19 member institutions. Likert scale questions gauged agreement with international EA surveillance guideline-derived statements. Multiple-choice questions assessed individual and institutional practices.ResultsThe response rate was 77%. Most respondents (80%) strongly agree or agree that EA surveillance endoscopy should follow a set schedule, while only 36% claimed to perform routine upper GI endoscopy regardless of symptoms. Many institutions (77%) have an aerodigestive clinic, even if some lack a multi-disciplinary EA team. Most physicians (72%) expressed strong interest in helping develop evidence-based guidelines.ConclusionsOur survey reveals physician agreement with current guidelines but weak adherence. Surveillance methods vary greatly, underscoring the lack of evidence-based data to guide EA care. Aerodigestive clinics may help implement surveillance schedules. Respondents support evidence-based protocols, which bodes well for care standardization. Results will inform the first multi-institutional EA databases in the United States (US), which will be essential for evidence-based care.Level of EvidenceThis is a prognosis study with level 4 evidence. 相似文献
103.
104.
Leyi Wang Saraswathi Lanka Debbie Cassout Nohra E. Mateus‐Pinilla Ganwu Li William C. Wilson Dongwan Yoo Paul Shelton Richard L. Fredrickson 《Transboundary and Emerging Diseases》2019,66(5):1809-1820
First described in 1955 in New Jersey, epizootic haemorrhagic disease (EHD) causes a severe clinical disease in wild and domestic ruminants worldwide. Epizootic haemorrhagic disease outbreaks occur in deer populations each year from summer to late autumn. The etiological agent is EHD virus (EHDV) which is a double‐stranded segmented icosahedral RNA virus. EHD virus utilizes point mutations and reassortment strategies to maintain viral fitness during infection. In 2018, EHDV serotype 2 was predominantly detected in deer in Illinois. Whole genome sequencing was conducted for two 2018 EHDV2 isolates (IL41747 and IL42218) and the sequence analyses indicated that IL42218 was a reassortant between different serotypes whereas IL41747 was a genetically stable strain. Our data suggest that multiple strains contribute to outbreaks each year. 相似文献
105.
106.
慢性肾脏病是一种以肾脏功能的损伤为主要表现,并可累及全身多脏器的慢性进展性疾病。中医辨证治疗本病在延缓病情、改善预后等方面具有显著的优势。通过中医理论研究及临床经验总结,笔者提出从“肾毒”论治慢性肾脏病,认为其不仅是本病的致病因素,更是重要的病理产物,是本病发生发展、迁延难愈的关键。在治疗上提出以“益肾元、解肾毒”为大法,并根据不同兼夹辨证施治,采用药对,长治缓图。以“肾毒”立论拟定的经验方苏茵解毒方,在临床治疗和实验研究上均显示出明显的效果,并已制备成院内制剂临床使用,在疗效及经济效益方面均具有显著的优势。 相似文献
107.
《Gait & posture》2022
BackgroundParkinson’s disease (PD) is a chronic and progressive neurodegenerative disease with no cure, presenting a challenging diagnosis and management. However, despite a significant number of criteria and guidelines have been proposed to improve the diagnosis of PD and to determine the PD stage, the gold standard for diagnosis and symptoms monitoring of PD is still mainly based on clinical evaluation, which includes several subjective factors. The use of machine learning (ML) algorithms in spatial-temporal gait parameters is an interesting advance with easy interpretation and objective factors that may assist in PD diagnostic and follow up.Research questionThis article studies ML algorithms for: i) distinguish people with PD vs. matched-healthy individuals; and ii) to discriminate PD stages, based on selected spatial-temporal parameters, including variability and asymmetry.MethodsGait data acquired from 63 people with PD with different levels of PD motor symptoms severity, and 63 matched-control group individuals, during self-selected walking speed, was study in the experiments.ResultsIn the PD diagnosis, a classification accuracy of 84.6 %, with a precision of 0.923 and a recall of 0.800, was achieved by the Naïve Bayes algorithm. We found four significant gait features in PD diagnosis: step length, velocity and width, and step width variability. As to the PD stage identification, the Random Forest outperformed the other studied ML algorithms, by reaching an Area Under the ROC curve of 0.786. We found two relevant gait features in identifying the PD stage: stride width variability and step double support time variability.SignificanceThe results showed that the studied ML algorithms have potential both to PD diagnosis and stage identification by analysing gait parameters. 相似文献
108.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
109.
《Gastroenterologia y hepatologia》2019,42(10):604-613
IntroductionSunlight exposure is the main source of vitamin D. Our aim was to describe both sun exposure and sun protection behaviour in a series of patients with inflammatory bowel disease (IBD), and to study their potential association with vitamin D concentration.Patients and methodsA cross sectional, observational study. The clinical-demographic variables were obtained via clinical interviews and medical history review. The sunlight exposure assessment was carried out using the Sun Exposure Questionnaire and the concentration of 25-hydroxy vitamin D (25OHD) was measured by an electro-chemiluminescence immunoassay. Questionnaires were conducted on quality of life, physical activity, weekly vitamin D intake and sun protection behaviour.Results149 patients were included. In 69% of patients, deficient or insufficient 25OHD values were recorded. 67% showed low sun exposure. A modest significant correlation was observed between the total score of the solar exposure questionnaire and the 25OHD concentration in the complete series (r = 0.226, P = .006) and in the summer (r = 0.274, P = .01). The sun protection behaviour questionnaire score did not influence the 25OHD concentration. In the multivariate analysis, only the presence of clinical activity was associated with low sun exposure (OR = 3.23).DiscussionSun exposure according to the questionnaire used was low, was associated with the presence of clinical activity and was weakly correlated with serum 25OHD concentration. More studies are needed to explore the use of individual questionnaires for sun exposure and its relationship with vitamin D in patients with IBD. 相似文献
110.